SCHEMBL5402498

SCHEMBL5402498

CCOc1ccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2cccs2)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
ATM Q13315 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
APP P05067 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
CTSD P07339 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5392305 0.97 ALDH1A1 (0.48) ALDH1A1MEN1KMT2ATDP1ATM
SCHEMBL5395679 0.94 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ATDP1ATM
SCHEMBL5403428 0.90 APP (0.49) ALDH1A1LMNAMAPTKDM4EHPGD
SCHEMBL4921807 0.87 LMNA (0.46) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL4931284 0.87 PPARA (0.46) ALDH1A1LMNAMAPTKDM4EHPGD
SCHEMBL5399251 0.87 POLB (0.46) ALDH1A1KMT2AATMLMNAGAA
SCHEMBL5406845 0.87 RAB9A (0.52) ALDH1A1MEN1KMT2ATDP1LMNA
SCHEMBL5398713 0.87 KMT2A (0.50) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL4928591 0.87 LMNA (0.47) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL5399160 0.87 RAB9A (0.46) ALDH1A1MEN1KMT2ATDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB ALDH1A1 1256/4885MEN1 891/4885KMT2A 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.